ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
9 announcements with these filters
Alembic Pharmaceuticals Limited has redeemed Commercial Papers (CP) worth Rs. 100 Crores. The redemption was completed on the maturity date of September 25, 2026.
Alembic Pharmaceuticals has redeemed Commercial Papers worth Rs. 150 Crore upon maturity on 23rd September 2026.
Alembic Pharmaceuticals has successfully redeemed Commercial Papers worth ₹150 Crore upon maturity. This confirms the repayment of the company's debt obligation.
Alembic Pharmaceuticals completed an unannounced USFDA onsite inspection at its Vadodara Bioequivalence Facility. The inspection concluded with zero Form 483 observations, a positive regulatory signal.
Alembic Pharmaceuticals incorporated a wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in the UAE for Rs. 0.26 Crore to explore new business opportunities in pharmaceuticals.
Alembic Pharmaceuticals incorporated a wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in Dubai to explore new business opportunities and distribution.
Alembic Pharmaceuticals Limited has appointed Mr. Chirag Shukla as the Company Secretary and Compliance Officer (Key Managerial Personnel), effective 20th August, 2026.
Alembic Pharmaceuticals' Company Secretary and Compliance Officer, Ms. Manisha Saraf, has resigned from her position effective August 10, 2026.
Q1FY27 revenue grew 26% to INR 2,150 Cr. Strategy focuses on US Generics volume growth, India Specialty therapeutic scale-up, and managing margin dilution from US branded investments.